Lineage Cell Therapeutics (AMEX:LCTX) 报告季度每股亏损$(0.02)，超过分析师共识预估的$(0.03)，提高了33.33%。 与去年同期每股亏损$(0.03)相比，这一数字提高了33.33%。 公司报告季度销售额$2.900百万，超过了分析师共识预估的$1.621百万，提高了78.88%。 与去年同期的销售额$2.100百万相比，这一数字增长了38.10%。

以上内容来自Benzinga Earnings专栏，原文如下：

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $2.900 million which beat the analyst consensus estimate of $1.621 million by 78.88 percent. This is a 38.10 percent increase over sales of $2.100 million the same period last year.